Treatment of mice with methamphetamine produces cell loss in the substantia nigra

Brain Research

Volumn 738, Issue 1, 1996, Pages 172-175

  Sonsalla, Patricia K ^a   Jochnowitz, Nina D ^a   Zeevalk, Gail D ^a   Oostveen, Jo A ^b   Hall, Edward D ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

animal model of Parkinson's disease; dopaminergic neurotoxicity; methamphetamine; mice; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); nigral cell loss; substantia nigra neuropathology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRAIN DIFFERENCE; SUBSTANTIA NIGRA;

EID: 0030605073     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00995-X     Document Type: Article

References (19)

1. Delle Donne K.T., Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271:1994;1320-1326.
2. Fuller, R.W., Comparison of MPTP and amphetamines as dopaminergic neurotoxins. In J.W. Langston and A. Young (Eds.), Neurotoxins and Neurodegenerative Disease, Annals of the New York Academy of Sciences, Vol. 648, The New York Academy of Sciences, New York, 1992, pp. 87-95.
3. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
4. Hess A., Desiderio C., McAuliffe W.G. Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: Immunohistochemical studies. J. Neurocytol. 19:1990;338-342.
5. Jonsson G., Nwanze E. Selective (+)-amphetamine neurotoxicity on striatal dopamine nerve terminals in the mouse. Br. J. Pharmacol. 77:1982;335-345.
6. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36:1976;363-371.
7. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57/B16J mouse. J. Pharmacol. Exp. Ther. 270:1994;741-751.
8. Pu C., Vorhees C.V. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev. Brain Res. 72:1993;325-328.
9. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
10. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233:1985;539-544.
11. Seiden, L.S. and Ricaurte, G.A., Neurotoxicity of methamphetamine and related drugs. In H.Y. Meltzer (Ed.), Psychoparmacology: The Third Generation of Progress. Raven Press, New York, 1987, pp. 359-366.
12. Sonsalla P.K., Gibb J.W., Hanson G.R. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp. Ther. 238:1986;932-937.
13. Sonsalla, P.K., Giovanni, A., Sieber, B.A., Delle Donne, K.T. and Manzino, L., Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. In J.W. Langston and A. Young (Eds.), Neurotoxins and Neurodegenerative Disease, Annals of the New York Academy of Sciences, Vol. 648. The New York Academy of Sciences, New York Academy of Sciences, New York, 1992, pp. 229-238.
14. Sonsalla P.K., Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129:1986;339-345.
15. Sonsalla P.K., Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 12:1988;345-354.
16. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1989;398-400.
17. Sonsalla P.K., Riorden D.E., Heikilla R.E. Competitive and non-competitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256:1991;506-512.
18. Sonsalla P.K., Zeevalk G.D., Manzino L., Giovanni A., Nicklas W.J. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem. 58:1992;1979-1982.
19. Trulson M.I., Cannon M.S., Faegg T.S., Raese J.D. Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: Tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res. Bull. 15:1985;569-577.